Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas

被引:64
作者
Engelsen, Ingeborg B. [1 ]
Stefansson, Ingunn
Aksten, Lars A.
Salvesen, Helga B.
机构
[1] Haukeland Univ Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Dept Pathol, N-5021 Bergen, Norway
[3] Univ Bergen, Gade Inst, Bergen, Norway
[4] Univ Bergen, Inst Clin Med, Bergen, Norway
关键词
endometrial carcinoma; curettage material; tumor markers; prognosis; survival;
D O I
10.1016/j.ajog.2006.02.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to investigate the prognostic impact of p53 and p16 expression in curettage material from patients with endometrial carcinoma. Study design: Preoperative curettage material from a population-based series of 236 endometrial carcinomas from Norway with long and complete follow-up was studied immunohistochemically for p53 and p 16 expression. Results: Pathologic expression of p53 and p16 was seen in 24% and 25%, respectively, and was significantly correlated with high International Federation of Gynecology and Obstetrics (FIGO) stage and serous/clear cell histologic subtypes. Pathologic p53 expression showed significant correlation with postmenopausal status, high grade, high tumor cell proliferation, and aneuploidy. Patients with normal expression had 85% 5-year survival compared with 51% and 50% when pathologic expression of p53 and p16, respectively. Five-year survival for patients with 2 pathologic markers was 13%, compared with 67% and 91% for 1 or no pathologic markers, respectively. Conclusion: Pathologic expression of p53 and p16 in curettage material identifies high-risk endometrial carcinoma patients with poor prognosis. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 32 条
[1]   Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level [J].
Alkushi, A ;
Lim, P ;
Coldman, A ;
Huntsman, D ;
Miller, D ;
Gilks, CB .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) :129-137
[2]   Endometrial cancer [J].
Amant, F ;
Moerman, P ;
Neven, P ;
Timmerman, D ;
Van Limbergen, E ;
Vergote, I .
LANCET, 2005, 366 (9484) :491-505
[3]   Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in International Federation of Gynecology and Obstetrics stage 1 and 2 endometrial carcinoma [J].
Baak, JPA ;
Snijders, W ;
van Diermen, B ;
van Diest, PJ ;
Diepenhorst, FW ;
Benraadt, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4214-4221
[4]  
BARAKAT RR, 1997, PRINCIPLES PRACTICE
[5]   Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer [J].
Cheng, YL ;
Lee, SC ;
Harn, HJ ;
Chen, CJ ;
Chang, YC ;
Chen, JC ;
Yu, CP .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (02) :221-228
[6]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[7]  
2-8
[8]   Predictors of final histology in patients with endometrial cancer [J].
Frumovitz, M ;
Singh, DK ;
Meyer, L ;
Smith, DH ;
Wertheim, I ;
Resnik, E ;
Bodurka, DC .
GYNECOLOGIC ONCOLOGY, 2004, 95 (03) :463-468
[9]   T cell development: Some cells get all the breaks [J].
Green, DR ;
Schuler, M .
NATURE IMMUNOLOGY, 2000, 1 (01) :15-17
[10]   Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma [J].
Hamel, NW ;
Sebo, TJ ;
Wilson, TO ;
Keeney, GL ;
Roche, PC ;
Suman, VJ ;
Hu, TC ;
Podratz, KC .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :192-198